See more : DermTech, Inc. (DMTKQ) Income Statement Analysis – Financial Results
Complete financial analysis of Plant Health Care plc (PLHCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Plant Health Care plc, a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Sonic Foundry, Inc. (SOFO) Income Statement Analysis – Financial Results
- South Jersey Industries Inc (SJIV) Income Statement Analysis – Financial Results
- Credit Suisse Asset Management Income Fund, Inc. (CIK) Income Statement Analysis – Financial Results
- Y. T. Realty Group Limited (0075.HK) Income Statement Analysis – Financial Results
- Armlogi Holding Corp. common stock (BTOC) Income Statement Analysis – Financial Results
Plant Health Care plc (PLHCF)
About Plant Health Care plc
Plant Health Care plc, together with its subsidiaries, provides agricultural biological products and technology solutions in the Americas, Mexico, and internationally. It offers products to enhance the yield and quality of crops, such as corn, soybeans, citrus, sugar cane, and rice, as well as fruits and vegetables. The company provides Harpin aß, a recombinant protein, which acts as a biostimulant to enhance the yield and quality of crops; and Saori, a vaccine for plants that promotes healthy growth of soybeans and helps them fight disease. It also distributes third-party biological products. The company was founded in 1995 and is headquartered in Holly Springs, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.48M | 11.77M | 8.43M | 6.61M | 6.44M | 8.13M | 7.69M | 6.33M | 7.51M | 6.88M | 7.46M | 7.75M | 7.85M | 7.09M | 16.68M | 19.85M | 18.30M | 13.68M | 10.22M | 8.61M | 8.08M |
| Cost of Revenue | 4.55M | 4.60M | 3.43M | 2.93M | 2.83M | 2.86M | 2.95M | 2.44M | 2.83M | 3.38M | 2.29M | 3.48M | 3.74M | 3.50M | 5.58M | 9.22M | 9.94M | 7.57M | 5.22M | 4.95M | 4.42M |
| Gross Profit | 6.93M | 7.17M | 5.00M | 3.68M | 3.60M | 5.27M | 4.73M | 3.89M | 4.68M | 3.50M | 5.16M | 4.27M | 4.11M | 3.59M | 11.10M | 10.63M | 8.35M | 6.11M | 5.00M | 3.66M | 3.66M |
| Gross Profit Ratio | 60.37% | 60.94% | 59.33% | 55.71% | 55.97% | 64.85% | 61.57% | 61.51% | 62.37% | 50.89% | 69.26% | 55.08% | 52.39% | 50.66% | 66.54% | 53.55% | 45.65% | 44.70% | 48.95% | 42.49% | 45.31% |
| Research & Development | 2.92M | 3.56M | 3.38M | 2.96M | 2.78M | 4.59M | 5.75M | 5.44M | 5.26M | 3.08M | 2.93M | 2.06M | 2.25M | 2.17M | 1.66M | 1.27M | 771.00K | 306.00K | 295.00K | 170.00K | 123.00K |
| General & Administrative | 4.22M | 8.29M | 4.32M | 1.70M | 1.81M | 5.56M | 1.79M | 7.29M | 4.48M | 3.77M | 3.61M | 5.74M | 1.48M | 1.17M | 3.85M | 1.46M | 1.88M | 1.26M | 6.42M | 5.12M | 4.54M |
| Selling & Marketing | 4.26M | 4.56M | 3.68M | 2.88M | 3.14M | 3.15M | 3.00M | 2.52M | 2.72M | 2.73M | 3.47M | 3.00M | 3.13M | 3.13M | 2.74M | 5.14M | 4.66M | 3.14M | 0.00 | 0.00 | 0.00 |
| SG&A | 8.71M | 12.85M | 8.00M | 4.58M | 4.95M | 8.71M | 4.78M | 9.80M | 7.20M | 6.50M | 7.08M | 8.74M | 4.61M | 4.30M | 6.59M | 6.60M | 6.54M | 4.40M | 6.42M | 5.12M | 4.54M |
| Other Expenses | -734.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.76M | -456.30K | 0.00 | 0.00 | 0.00 | 0.00 | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 366.00K |
| Operating Expenses | 11.63M | 16.41M | 11.38M | 7.25M | 7.73M | 13.30M | 10.53M | 15.24M | 12.46M | 9.58M | 10.01M | 10.80M | 11.24M | 10.83M | 12.86M | 14.65M | 13.60M | 8.94M | 7.88M | 5.85M | 4.54M |
| Cost & Expenses | 16.18M | 21.01M | 14.81M | 10.18M | 10.56M | 16.16M | 13.49M | 17.68M | 15.28M | 12.96M | 12.30M | 14.28M | 14.98M | 14.33M | 18.44M | 23.87M | 23.54M | 16.51M | 13.09M | 10.80M | 8.96M |
| Interest Income | 164.88K | 113.00K | 27.00K | 295.00K | 56.00K | 70.00K | 87.00K | 52.00K | 95.00K | 119.00K | 38.00K | 84.00K | 82.00K | 239.00K | 249.00K | 184.00K | 177.00K | 275.00K | 64.00K | 44.00K | 0.00 |
| Interest Expense | 80.90K | 197.00K | 61.00K | 31.00K | 38.00K | 1.00K | 2.00K | 2.00K | 2.00K | 3.00K | 1.00K | 4.00K | 7.00K | 13.00K | 25.00K | 46.00K | 302.00K | 335.00K | 96.00K | 299.00K | 366.00K |
| Depreciation & Amortization | 742.47K | 655.86K | 557.31K | 681.15K | 803.74K | 561.63K | 690.12K | 578.77K | 436.00K | 384.00K | 381.00K | 427.00K | 423.00K | 456.00K | 732.00K | 466.00K | 504.00K | 250.00K | 231.00K | 186.00K | 138.00K |
| EBITDA | -3.96M | -9.02M | -5.79M | -3.27M | -3.73M | -7.45M | -5.14M | -10.72M | -7.25M | -5.57M | -6.53M | -6.03M | -6.55M | -7.18M | -1.13M | -3.67M | -4.72M | -2.45M | -1.50M | -1.95M | -391.00K |
| EBITDA Ratio | -34.54% | -71.87% | -68.63% | -39.84% | -47.08% | -90.49% | -65.80% | -168.53% | -96.50% | -81.02% | -59.41% | -77.64% | -83.38% | -97.50% | 0.86% | -18.30% | -24.95% | -16.82% | -25.20% | -22.69% | -9.09% |
| Operating Income | -4.71M | -9.24M | -6.38M | -3.57M | -4.13M | -8.03M | -5.80M | -11.35M | -7.78M | -6.08M | -6.95M | -6.53M | -7.05M | -7.88M | -1.83M | -4.10M | -5.24M | -2.87M | -2.87M | -2.63M | -877.00K |
| Operating Income Ratio | -41.00% | -78.51% | -75.68% | -53.97% | -64.12% | -98.83% | -75.48% | -179.33% | -103.57% | -88.33% | -93.17% | -84.24% | -89.81% | -111.15% | -10.96% | -20.64% | -28.65% | -20.95% | -28.07% | -30.48% | -10.85% |
| Total Other Income/Expenses | 108.56K | -209.00K | -34.00K | 264.00K | 285.00K | 89.00K | 85.00K | 50.00K | 93.00K | 116.00K | -2.06M | 57.00K | 75.00K | 226.47K | 1.15M | -121.03K | -125.90K | -59.58K | -19.00K | -1.52M | -205.00K |
| Income Before Tax | -4.60M | -9.45M | -6.42M | -3.30M | -3.84M | -7.94M | -5.72M | -11.30M | -7.68M | -5.96M | -6.91M | -6.45M | -6.98M | -7.65M | -679.00K | -4.22M | -5.37M | -2.93M | -2.90M | -2.88M | -1.24M |
| Income Before Tax Ratio | -40.06% | -80.28% | -76.08% | -49.98% | -59.70% | -97.74% | -74.38% | -178.54% | -102.33% | -86.64% | -92.68% | -83.20% | -88.86% | -107.96% | -4.07% | -21.25% | -29.33% | -21.39% | -28.39% | -33.45% | -15.38% |
| Income Tax Expense | -500.78K | 36.00K | -111.00K | -80.00K | -158.00K | -252.00K | -262.00K | -83.00K | 37.00K | 169.00K | -117.00K | 55.00K | 157.00K | 40.00K | 85.00K | 62.00K | 47.00K | 72.00K | 121.00K | 52.00K | 70.00K |
| Net Income | -4.10M | -9.48M | -6.30M | -3.22M | -3.68M | -7.69M | -5.45M | -11.22M | -7.72M | -6.13M | -6.88M | -6.57M | -5.14M | -7.56M | -1.33M | -4.22M | -5.42M | -3.03M | -3.05M | -2.95M | -1.35M |
| Net Income Ratio | -35.70% | -80.59% | -74.76% | -48.77% | -57.24% | -94.64% | -70.97% | -177.23% | -102.82% | -89.10% | -92.30% | -84.79% | -65.47% | -106.69% | -7.98% | -21.25% | -29.65% | -22.14% | -29.83% | -34.21% | -16.67% |
| EPS | -0.01 | -0.03 | -0.02 | -0.01 | -0.02 | -0.05 | -0.04 | -0.11 | -0.11 | -0.09 | -0.10 | -0.12 | -0.10 | -0.14 | -0.03 | -0.09 | -0.13 | -0.08 | -0.10 | -0.14 | -0.10 |
| EPS Diluted | -0.01 | -0.03 | -0.02 | -0.01 | -0.02 | -0.05 | -0.04 | -0.11 | -0.11 | -0.09 | -0.10 | -0.12 | -0.10 | -0.14 | -0.03 | -0.09 | -0.13 | -0.08 | -0.10 | -0.14 | -0.10 |
| Weighted Avg Shares Out | 325.59M | 305.15M | 292.20M | 245.27M | 178.03M | 168.85M | 147.82M | 100.37M | 71.74M | 71.49M | 65.60M | 53.26M | 53.06M | 52.80M | 49.73M | 44.75M | 42.41M | 36.84M | 30.05M | 21.02M | 13.22M |
| Weighted Avg Shares Out (Dil) | 325.59M | 305.15M | 292.20M | 245.27M | 178.03M | 168.85M | 147.82M | 100.37M | 71.74M | 71.49M | 65.60M | 53.26M | 53.06M | 52.80M | 49.73M | 44.75M | 42.41M | 36.84M | 30.05M | 21.02M | 13.22M |
Plant Health Care shares rise 8% on Brazilian green light
Shares in Plant Health Care PLC (AIM:PHC, OTCQB:PLHCF) nudged 8% higher following Brazil's federal approval of its innovative nematicide, TEIKK™, for the 2024/25 soybean season. TEIKKO, developed from the company's PREtec peptide platform, provides a new approach to controlling microscopic...
Plant Health Care shares grow on Brazil fungicide approval
Shares in Plant Health Care PLC (AIM:PHC, OTCQB:PLHCF) grew almost 6% on Friday morning as the company confirmed its fungicide had been approved for use by the Brazilian government. AIM-listed Plant Health Care's biochemical fungicide, PHC279, is designed to control...
Bellway and Ashtead results lead the way on Tuesday
With housebuilders on a sticky wicket at present, amid rising interest rates, demand slowing and inflation putting pressure on costs, a Bellway PLC (LSE:BWY) update could be interesting. With a recent update from a sector peer showing sales slowing again as...
Source: https://incomestatements.info
Category: Stock Reports